None listed
Conditions
Interventions
Intervention1: TurmXTRA: One capsule of TurmXTRA 60N 250 mg to be taken once a day in the morning 30 minutes before breakfast for a duration of 60 days.
Control Intervention1: Placebo: One capsule of
Sponsors
Nutriventia Limited Unit
Laila Nutraceuticals
Eligibility
Inclusion criteria
Inclusion criteria: 1. Healthy women participants from 18-40 years of age declared healthy after assessing medical history, physical examination and clinical judgment of the investigator. 2. Presence of blemish on face (Post inflammatory hyperpigmentation, acne marks, age spots, sun spots) with otherwise healthy skin on the test area. 3. Willingness to discontinue the use of other cosmetic products on face during the course of the study. 4. Accepting not to use topical or / and oral products with the same end benefit or products containing sunscreen which might interfere with the study results, during the entire study duration. 5. Cooperating, informed of the need and duration of the examinations, and ready to comply with protocol procedures. 6. Having signed a Consent Form, after being informed orally and in writing of all information concerning the study procedures and study objectives. 7. Willingness to avoid intense UV exposure as far as possible for the entire study duration. 8. Results of screening test are within normal range or considered not clinically significant by the principal Investigator.
Exclusion criteria
Exclusion criteria: 1. Male participants. 2. Peri-menopausal and post-menopausal women. 3. Pregnant women as confirmed by UPT or lactating women. 4. Presence of any cutaneous conditions on test site (scars, moles, papules etc). 5. Presence of any clinically significant systemic or cutaneous disease, which may interfere with study treatments or procedures. 6. History or presence of substance abuse (alcohol, drugs, smoking). 7. Subject likely to undergo any surgery during the period of the study or within 01 month of study completion. 8. Participation in any other experimental Investigational study within last 1 month as identified during screening on visit 1 (V1). 9. Presence of any hard damage to skin (e.g., excessive sunburn or suntan). 10. History of use of collagen peptide containing supplement in the past 6 months. 11. History of consumption of high doses of vitamin C (>500 mg a day) or any other high dose antioxidant product in the past 1 month. 12. Subjects on any nutritional supplement or consuming any therapeutic medication for any disorder for last 45 days. 13. Subjects with known allergies to any of the ingredients of the study products 14. Individuals with chronic gastrointestinal issues such as frequent indigestion, GERD. 15. Subjects with severe acne. 16. Subjects with the history of gallstones or bile duct obstruction disorders. 17. Subjects with the history of bleeding disorders. 18. Difficulty in swallowing and retaining oral formulation. 19. Any history of difficulty in accessing veins to draw blood.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison between Test product and placebo for change inblemishes/spot areas on facial skin via 3D instrumentation from baseline to Day 60.Timepoint: Day 0, Day 60 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Comparison between test product & placebo for change in blemishes/spot areas on facial skin 2. Comparison between test product & placebo for change in Skin tone evenness, skin hydration, TEWL & Gloss.Timepoint: Day 0, Day 15, Day 30, Day 60 | — |
Countries
India
Contacts
Public ContactMs Preetha Paul
Clinical Aesthetics and Investigative Management Service Pvt. Ltd. (C.L.A.I.M.S.PVT.LTD.)
Outcome results
None listed